Neuroscience

Business World: Biogen Idec, Elan, & Tysabri (Natalizumab) (cont.)

Additional information in follow-up to this morning's Boston Globe report, from Bloomberg:

Elan, Biogen Decline on Report of New Tysabri Illness

June 2 (Bloomberg) -- Shares of Elan Corp. and Biogen Idec Inc. tumbled after a fourth possible case of a rare and often fatal nerve disorder was reported in a patient taking the companies' withdrawn Tysabri multiple-sclerosis drug.

Biogen and Elan are investigating the newest report of a Tysabri patient with symptoms consistent with the disorder, Lenore Gelb, a U.S. Food and Drug Administration spokeswoman, said today. Elan shares fell 83 cents, or 13 percent, to 5.47 euros in Dublin. Biogen lost 4.3 percent on the Nasdaq Stock Market. The Boston Globe reported the case earlier today.

The report hasn't been confirmed to be the disease, called progressive multifocal leukoencephalopathy, as have three other cases, Gelb said. Biogen and Elan withdrew Tysabri Feb. 28 after the potential $1 billion drug was linked to the disorder. Two of three patients who developed the disease have died.

[ ... Read the full report ... ]
-
Anthony H. Risser | neuroscience | neuropsychology | brain

- Business World: Biogen Idec, Elan, & Tysabri (natalizumab)
From the AP: Elan Shares Jump As Tysabri to Get Review By THE ASSOCIATED PRESS Published: November 18, 2005 Filed at 12:52 p.m. ET DUBLIN, Ireland (AP) -- Shares in Irish drug maker Elan Corp. PLC jumped Friday...

- Business World: Biogen Idec, Elan, Tysabri (natalizumab), And Multiple Sclerosis
From Bloomberg via the New York Times:Move to Reinstate Multiple Sclerosis Drug Published: September 21, 2005 By Bloomberg News Biogen Idec Inc. and the Elan Corporation said yesterday that they would seek federal regulatory approval to resume sales...

- Business World: Biogen Idec, Elan, & Tysabri (natalizumab) And Avonex (interferon Beta-1a)
From: RTE Ireland:Elan releases Tysabri trial figures July 19, 2005 11:09 Pharmaceutical company Elan has released figures showing that its suspended Tysabri drug improved the effectiveness of Biogen's Avonex in the treatment of multiple sclerosis....

- Business World: Biogen Idec, Elan, & Tysabri (natalizumab)
From today's Boston Globe:Biogen MS drug gets lift from reports Medical journal suggests Tysabri may make a return By Jeffrey Krasner The Boston Globe 10 June 2005 Biogen Idec Inc.'s drug Tysabri might be safely given to multiple sclerosis patients...

- Business World: Tysabri (natalizumab) And Biogen Idec
From today's Boston Globe: Biogen Idec's top lawyer quits amid investigation By Jeffrey Krasner The Boston Globe March 10, 2005 Thomas J. Bucknum, Biogen Idec's longtime top lawyer, resigned suddenly yesterday amid an inquiry by the Securities...

Neuroscience